Paradigm Biopharmaceuticals receives positive results for Ross River clinical trial
The trial was treating patients with joint pain or joint stiffness.
Company
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a drug repurposing company driven by core competencies and experience at board and executive level in clinical and commercial pharmaceutical development. The company’s approach is to take an existing approved drug, which has demonstrated safety in its approved indications, and repurposing the drug in a new patented therapeutic application. Paradigm’s pipeline indications cover the use of pharmaceutical compound Pentosan Polysulfate Sodium (PPS), supported by full patent and IP protection and its immediate commercial focus is the repurposing of PPS for the treatment of Osteoarthritis (OA).
175 stories · page 6 of 9
Paradigm Biopharmaceuticals receives more positive real-world patient data
Doctors can administer the treatment to patients under the TGA Special Access Scheme.
Investments and investor services
S&P/ASX 200 set for positive start as US markets have Monday holiday
Monday is Memorial Day in the US meaning stock markets are closed.
Paradigm Biopharmaceuticals completes retail component of $26.3 million entitlement offer
The retail entitlement offer had a take-up rate of about 54.7% for acceptances of entitlements and applications for additional shares by eligible retail shareholders.
Paradigm Biopharmaceuticals completes institutional component of $26.3 million entitlement offer
Along with the entitlement offer, Paradigm has raised $51.6 million via a placement to professional, institutional and sophisticated investors.
Paradigm Biopharmaceuticals director buys shares on-market
The company has today commenced the retail component of its $77.9 million capital raising.
Paradigm Biopharmaceuticals secures $61.3 million in first stage of raising
The capital raising has attracted a number of international institutional investors.
Paradigm Biopharmaceuticals phase 2b trial achieves key endpoints in OA of the knee
OA remains the most common form of joint disease globally, affecting over 30 million adults in the US alone.
Paradigm Biopharmaceuticals raising $77.9 million to fund its pivotal phase 3 OA trial
In conjunction with the capital raise, Paradigm has revealed that it has successfully met the primary and secondary endpoints of its phase 2b trial in OA of the knee.
Paradigm Biopharmaceuticals gets a speeding ticket for 18% price increase
Over the past year, shares have come from 29 cents to be trading at around $1.90.
Paradigm Biopharmaceuticals director shows confidence with on-market share purchase
The company has begun discussions with International key opinion leaders for mucopolysaccharidoses (MPS) clinical trial design and site selection.
Investments and investor services
Carnarvon Petroleum into S&P/ASX 300 – AC8, BGL, PAR into All Ordinaries
The rebalance changes are effective at the open of trading on March 18, 2019.
Paradigm Biopharmaceuticals moving towards phase 2/3 MPS clinical trial
MPS or mucopolysaccharidoses is an orphan indication with market exclusivity and high profit margins.
Paradigm Biopharmaceuticals to court partners and licensees for OA drug commercialisation
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
Paradigm Biopharmaceutical shares surge on clinical trial success
The trial met the primary endpoint with a change in the knee injury and OA outcome score, confirming the potential for safe and effective treatment with iPPS.
Paradigm Biopharmaceuticals to talk clinical trial results on conference call tomorrow morning
The call will discuss the phase IIb randomised double-blind placebo controlled multicentre study.
Paradigm Biopharmaceuticals has results pending for phase 2b clinical trial
A trading halt will remain in place until the start of trading on Tuesday, December 18, or when an announcement is released.
Paradigm Biopharmaceuticals chief executive Paul Rennie buys more shares
Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form
Paradigm Biopharmaceuticals gets more real world evidence of treatment success
Patients access the treatment through their doctor under the TGA’s Special Access Scheme.
Paradigm Biopharmaceuticals gains on market with upcoming clinical trial read-out, wider treatment potential
The readout of clinical trials is expected this month.